PMID- 21877883
OWN - NLM
STAT- MEDLINE
DCOM- 20120803
LR  - 20211020
IS  - 1029-2403 (Electronic)
IS  - 1042-8194 (Print)
IS  - 1026-8022 (Linking)
VI  - 53
IP  - 3
DP  - 2012 Mar
TI  - Outpatient consolidation treatment with clofarabine in a phase 2 study of older 
      adult patients with previously untreated acute myelogenous leukemia.
PG  - 435-40
LID - 10.3109/10428194.2011.616960 [doi]
AB  - This report describes outpatient (OP) administration of clofarabine in older 
      patients (>/=60 years) with untreated acute myelogenous leukemia (AML). Overall, 
      112 patients underwent clofarabine induction. Clofarabine was administered to 35 
      OPs for a total of 72 OP cycles, with 81% of these cycles representing 
      consolidation treatment. Median length of hospital stay was 0-6 days and 5-25 
      days across OP and inpatient (IP) cycles, respectively. The most common adverse 
      events (AEs) were nausea, vomiting, diarrhea, febrile neutropenia, edema, 
      hypokalemia and pneumonia. The overall frequency of treatment-emergent grade >/=3 
      AEs and serious AEs was generally not different with IP or OP administration of 
      clofarabine. No deaths were reported within 30 days following OP or IP 
      consolidation cycles. In the appropriately selected older patient, OP 
      administration of clofarabine consolidation appears feasible, is as well 
      tolerated as IP administration and has potential to contribute to the quality of 
      life in elderly patients with AML.
FAU - Claxton, David
AU  - Claxton D
AD  - Division of Hematology/Oncology, Penn State Milton S. Hershey Medical Center, 
      Hershey, PA 17033, USA. dclaxton@hmc.psu.edu
FAU - Erba, Harry P
AU  - Erba HP
FAU - Faderl, Stefan
AU  - Faderl S
FAU - Arellano, Martha
AU  - Arellano M
FAU - Lyons, Roger M
AU  - Lyons RM
FAU - Kovacsovics, Tibor
AU  - Kovacsovics T
FAU - Gabrilove, Janice
AU  - Gabrilove J
FAU - Huebner, Dirk
AU  - Huebner D
FAU - Gandhi, Pritesh J
AU  - Gandhi PJ
FAU - Kantarjian, Hagop
AU  - Kantarjian H
CN  - CLASSIC II Investigators
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20111024
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Adenine Nucleotides)
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0 (Arabinonucleosides)
RN  - 762RDY0Y2H (Clofarabine)
SB  - IM
MH  - Acute Kidney Injury/chemically induced
MH  - Adenine Nucleotides/administration & dosage/adverse effects/*therapeutic use
MH  - Aged
MH  - *Ambulatory Care
MH  - Antimetabolites, Antineoplastic/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Arabinonucleosides/administration & dosage/adverse effects/*therapeutic use
MH  - Clofarabine
MH  - *Consolidation Chemotherapy
MH  - Drug Administration Schedule
MH  - Female
MH  - Gastrointestinal Diseases/chemically induced
MH  - Humans
MH  - Hypokalemia/chemically induced
MH  - Inpatients/statistics & numerical data
MH  - Length of Stay
MH  - Leukemia, Myeloid, Acute/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Neutropenia/chemically induced/complications
MH  - Outpatients/statistics & numerical data
MH  - Pneumonia/etiology
MH  - Quality of Life
PMC - PMC5556977
MID - NIHMS888478
COIS- Potential conflict of interest: Disclosure forms provided by the authors are 
      available with the full text of this article at www.informahealthcare.com/lal.
EDAT- 2011/09/01 06:00
MHDA- 2012/08/04 06:00
PMCR- 2017/08/15
CRDT- 2011/09/01 06:00
PHST- 2011/09/01 06:00 [entrez]
PHST- 2011/09/01 06:00 [pubmed]
PHST- 2012/08/04 06:00 [medline]
PHST- 2017/08/15 00:00 [pmc-release]
AID - 10.3109/10428194.2011.616960 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2012 Mar;53(3):435-40. doi: 10.3109/10428194.2011.616960. Epub 
      2011 Oct 24.